Literature DB >> 27942190

Ang-2 but not Ang-1 expression in perivascular soft tissue tumors.

Swati Shrestha1, Jia Shen2, Paulina Giacomelli3, Michelle A Scott4, Chia Soo5, Kang Ting2, Bruno Péault6, Sarah M Dry3, Aaron W James7.   

Abstract

Perivascular soft tissue tumors are relatively uncommon neoplasms of unclear line of differentiation, although most are presumed to originate from pericytes. Previously, we reported a shared immunophenotype across these related tumor types. Here, we extend these findings to examine the expression of the pericyte markers angiopoietin-1 and -2 (Ang-1 and -2) among perivascular soft tissue tumors. Results showed consistent Ang-2 but not Ang-1 expression across tumor types. In summary, the absence of Ang-1 expression distinguishes perivascular from vascular soft tissue tumors. Ang-2 expression is present across perivascular soft tissue tumors, with some variation between histologic subtypes.

Entities:  

Keywords:  Angioleiomyoma; Angiopoietin; Glomus tumor; Myopericytoma; Pericyte

Year:  2016        PMID: 27942190      PMCID: PMC5134090          DOI: 10.1016/j.jor.2016.07.003

Source DB:  PubMed          Journal:  J Orthop        ISSN: 0972-978X


  23 in total

Review 1.  Endothelial/pericyte interactions.

Authors:  Annika Armulik; Alexandra Abramsson; Christer Betsholtz
Journal:  Circ Res       Date:  2005-09-16       Impact factor: 17.367

2.  Platelet-derived growth factor receptor (beta-subunit) immunoreactivity in soft tissue tumors.

Authors:  C Palman; D F Bowen-Pope; J J Brooks
Journal:  Lab Invest       Date:  1992-01       Impact factor: 5.662

3.  Novel MIR143-NOTCH fusions in benign and malignant glomus tumors.

Authors:  Juan-Miguel Mosquera; Andrea Sboner; Lei Zhang; Chun-Liang Chen; Yun-Shao Sung; Hsiao-Wei Chen; Narasimhan P Agaram; Daniel Briskin; Basma M Basha; Samuel Singer; Mark A Rubin; Thomas Tuschl; Cristina R Antonescu
Journal:  Genes Chromosomes Cancer       Date:  2013-09-02       Impact factor: 5.006

4.  Pharmacokinetic drug-drug interaction study of the angiopoietin-1/angiopoietin-2-inhibiting peptibody trebananib (AMG 386) and paclitaxel in patients with advanced solid tumors.

Authors:  Jennifer R Diamond; Benjamin Wu; Neeraj Agarwal; Daniel W Bowles; Elaine T Lam; Theresa L Werner; Erik Rasmussen; Erick Gamelin; Felipe Soto; Greg Friberg; Yu-Nien Sun; Sunil Sharma
Journal:  Invest New Drugs       Date:  2015-04-21       Impact factor: 3.850

5.  Atypical and malignant glomus tumors: analysis of 52 cases, with a proposal for the reclassification of glomus tumors.

Authors:  A L Folpe; J C Fanburg-Smith; M Miettinen; S W Weiss
Journal:  Am J Surg Pathol       Date:  2001-01       Impact factor: 6.394

6.  Alliance A091103 a phase II study of the angiopoietin 1 and 2 peptibody trebananib for the treatment of angiosarcoma.

Authors:  Sandra P D' Angelo; Michelle R Mahoney; Brian A Van Tine; Douglas R Adkins; Maria T Grosse Perdekamp; Mercedes M Condy; Jason J Luke; Eliza Woodward Hartley; Cristina R Antonescu; William D Tap; Gary K Schwartz
Journal:  Cancer Chemother Pharmacol       Date:  2015-02-12       Impact factor: 3.333

7.  Trebananib (AMG 386) in Combination With Sunitinib in Patients With Metastatic Renal Cell Cancer: An Open-Label, Multicenter, Phase II Study.

Authors:  Michael B Atkins; Gwenaelle Gravis; Kazimierz Drosik; Tomasz Demkow; Piotr Tomczak; Shirley S Wong; M Dror Michaelson; Toni K Choueiri; Benjamin Wu; Lynn Navale; Douglas Warner; Alain Ravaud
Journal:  J Clin Oncol       Date:  2015-08-24       Impact factor: 44.544

Review 8.  Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer.

Authors:  Khalid Al Wadi; Prafull Ghatage
Journal:  Expert Opin Pharmacother       Date:  2016-03-21       Impact factor: 3.889

9.  Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels.

Authors:  Beverly L Falcón; Hiroya Hashizume; Petros Koumoutsakos; Jeyling Chou; James V Bready; Angela Coxon; Jonathan D Oliner; Donald M McDonald
Journal:  Am J Pathol       Date:  2009-10-08       Impact factor: 4.307

10.  A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI♯9041).

Authors:  Joanne W Chiu; Sebastien J Hotte; Christian K Kollmannsberger; Daniel J Renouf; David W Cescon; David Hedley; Sue Chow; Jeffrey Moscow; Zhuo Chen; Meghan Perry; Ivan Diaz-Padilla; David Tan; Hal Hirte; Elaine McWhirter; Helen Chen; Lillian L Siu; Philippe L Bedard
Journal:  Invest New Drugs       Date:  2015-12-19       Impact factor: 3.850

View more
  2 in total

1.  Glomus tumors of the trachea: 2 case reports and a review of the literature.

Authors:  Chun Wang; Yuan Ma; Xin Zhao; Pei-Li Sun; Ying-Ming Zhang; Mao Huang; Yan Zhu; Shu-Xian Jin
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

2.  Myopericytoma/myopericytomatosis of the lower extremity in two young patients: a recently designated rare soft tissue neoplasm.

Authors:  Katherine Peters; Jamie T Caracciolo; Evita Henderson-Jackson; Odion Binitie
Journal:  Radiol Case Rep       Date:  2017-11-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.